Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published Date March 2010 Volume 2010:6 Pages 145—155

DOI http://dx.doi.org/10.2147/VHRM.S8216

Published 9 March 2010

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: a systematic review and meta-analysis

Guo H, Ling C, Ma YY, Zhou LX, Zhao L

OncoTargets and Therapy 2015, 8:1503-1509

Published Date: 19 June 2015

A bibliometric analysis of the 100 most influential papers on COPD

Gu WC, Yuan YP, Yang H, Qi GS, Jin XY, Yan J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:667-676

Published Date: 25 March 2015

Analysis and differentiation of seminal plasma via polarized SERS spectroscopy

Chen X, Huang Z, Feng S, Chen J, Wang L, Lu P, Zeng H, Chen R

International Journal of Nanomedicine 2012, 7:6115-6121

Published Date: 17 December 2012

Biocompatibility of magnetic Fe3O4 nanoparticles and their cytotoxic effect on MCF-7 cells

Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ

International Journal of Nanomedicine 2012, 7:4973-4982

Published Date: 14 September 2012

Effects of a 6-month exercise program pilot study on walking economy, peak physiological characteristics, and walking performance in patients with peripheral arterial disease

Crowther RG, Leicht AS, Spinks WL, Sangla K, Quigley F, Golledge J

Vascular Health and Risk Management 2012, 8:225-232

Published Date: 17 April 2012

Simple equations to predict concentric lower-body muscle power in older adults using the 30-second chair-rise test: a pilot study

Wesley N Smith, Gianluca Del Rossi, Jessica B Adams, et al

Clinical Interventions in Aging 2010, 5:173-180

Published Date: 7 July 2010

Does plasmin have anticoagulant activity?

Jane Hoover-Plow

Vascular Health and Risk Management 2010, 6:199-205

Published Date: 26 March 2010

Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients

Jamison Wyatt, Shailesh Nandish, Rene Oliveros, et al

Vascular Health and Risk Management 2010, 6:1-8

Published Date: 23 December 2009

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009